

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-67) VOLRUSTOMIG
 PRONUNCIATION vol roos' toe mig
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAME

Immunoglobulin G1 [134-cysteine,228-valine,242-phenylalanine,243-glutamic acid,339-serine,362-cysteine,374-tryptophan], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal MEDI5752 γ 1-chain), disulfide with [122-cysteine,212-valine] human monoclonal MEDI5752 λ -chain, (234 \rightarrow 231')(237 \rightarrow 234')(362 \rightarrow 354') tris(disulfide) with immunoglobulin G1 [239-phenylalanine,240-glutamic acid,336-serine,354-cysteine,371-serine,373-alanine,412-valine] anti-(human programmed cell death protein 1) (human-*Mus musculus* monoclonal MEDI5752 γ 1-chain) disulfide with human-*Mus musculus* monoclonal MEDI5752 κ -chain

STRUCTURAL FORMULA

Heavy chain (X, anti-CTLA4 Heavy chain)

QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYGMHWVRQA	PGKGLEWVAV	50
IWYDGSNKYY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARDP	100
RGATLYYYYY	GMDVWGQGT	VTVSSASTKG	PSVCLAPSS	KSTSGGTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSS	200
LGTQTYICNV	NHKPSNTKVD	KRVEPKSVDK	THTCPPCPAP	EFEGGPSVFL	250
FPPKPKDTLM	ISRTPEVTCV	VVDVSHEDPE	VKFNWYVDGV	EVHNAKTKPR	300
EEQYNSTYRV	VSVLTVLHQD	WLNKEYKCK	VSNKALPASI	EKTIISKAKGQ	350
PREPQVYTLF	PCREEMTKNQ	VSLWCLVKGF	YPSDIAVEWE	SNGQPENNYK	400
TTPPVLDSDG	SFFLYSKLTV	DKSRWQQGNV	FSCSVMHEAL	HNHYTQKSLS	450
LSPGK					447

Light chain (X', anti-CTLA4 Heavy chain)

DIQMTQSPSS	LSASVGDRVT	ITCRASQSN	SYLDWYQQKP	GKAPKLLIYA	50'
ASSLQSGVPS	RFSGSGSGTD	FTLTISLQP	EDFATYYCQQ	YYSTPFTFGP	100'
GTKVEIKGQP	KAAPSVTLFP	PCSEELQANK	ATLVCLISDF	YPGAVTVAWK	150'
ADSSPVKAGV	ETTPSKQSN	NKYAASSYLS	LTPEQWKSHR	SYSCQVTHEG	200'
STVEKTVAPT	EVS				213'

Heavy chain (X'', anti-PD1)

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	DYGMHWVRQA	PGKGLEWVAV	50''
ISSGSYTIYS	ADSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCARRA	100''
PNSFYEYFFD	YWGQGTFTVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150''
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	200''
QTYICNVNKH	PSNTKVDKRV	EPKSCDKTHT	CPPCPAPEFE	GGPSVFLFPP	250''
KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	300''
YNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KALPASIEKT	ISKAKGQPRE	350''
PQVCTLPSPR	EEMTKNQVSL	SCAVKGFYPS	DIAVEWESNG	QPENNYKTP	400''
PVLDSDGSFF	LVSKLTVDKS	RWQQGNVFC	SVMHEALHNH	YTQKSLSLSP	450''
GK					452''

Light chain (X''', anti-PD1)

QIVLTQSPAT	LSLSPGERAT	LSCSASSKHT	NLYWSRHMVW	YQQKPGQAPR	50'
LLIYLTSNRA	TGIPARFSGS	GSQDFTLTI	SSLEPEDFAV	YYCQQWSSNP	100'
FTFGQGTKLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYPREAK	150'
VQWVKVDNALQ	SGNSQESVTE	QDSKDYSTYSL	SSTLTLSKAD	YEKHKVYACE	200'

VTHQGLSSPV TKSFNREGC

219'

Disulfide bridges

22-96	22''-96''	23'-88'	23'''-93'''	135'-194'	139'''-199'''	152-208	149''-205''
134-122''	225''-209'''	234-231''	237-234''	269-329	266''-326''	362-354''	375-433
372''-430''							

Glycosylation sites (N)

305 302''

MOLECULAR FORMULA $C_{6528}H_{10050}N_{1736}O_{2026}S_{47}$

MOLECULAR WEIGHT 146.8 kDa

TRADEMARK None as yet

SPONSOR AstraZeneca

CODE DESIGNATIONS MEDI5752

CAS REGISTRY NUMBER 2407760-40-9

UNII K96EGJ218N

WHO NUMBER 12168

gbk